Antiplatelet Therapy
Personalised Antiplatelet Therapy - it's possible now
Everyone agrees that personalised antiplatelet therapy is desirable and looks forward to the future when personalised antiplatelet therapy is possible. But the future is now, and personalised antiplatelet therapy is possible today. What you need are two end point measurements:
- A patient's maximum platelet function
- Platelet inhibition relative to their own maximal platelet function
Haemoscope's TEGŪ 5000 system with our new PlateletMapping™ assays provide this information... today.
- TEGŪ analysis provides the measure of maximum platelet function, so you know the degree of hypercoagulability and extent of inhibition needed
The PlateletMapping assay reports the percent inhibition and net platelet function.
- So you know:
- Whether patients are resistant to antiplatelet therapy
- The effect of the therapy
- Whether they are at their therapeutic level
- Their risk for ischemic or bleeding event
Patients may be at risk for an ischemic event when they are prothrombotic and antiplatelet drugs are suspended before surgery, or at risk for a bleeding event post-op when they are not prothrombotic and are on antiplatelet agents. The rationale for using two end points is illustrated in this graphic, which shows the effect of 50% inhibition on different patients: (click to view full size)
